Trial Outcomes & Findings for From Innovation to Solutions: Childhood Influenza Vaccination Planning (NCT NCT01664793)

NCT ID: NCT01664793

Last Updated: 2014-11-24

Results Overview

Influenza vaccination rates in each arm at the end of year 1

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

87665 participants

Primary outcome timeframe

3/1/2011-2/29/2012

Results posted on

2014-11-24

Participant Flow

Participant milestones

Participant milestones
Measure
Intervention Group
Children who are active patients of 10 diverse pediatric and family medicine practices and who had at least one visit between 3/1/2011 and 2/29/2012 will serve as the Intervention group; n=49,039. Intervention sites will use the 4 Pillars toolkit along with early season vaccine to promote increases in childhood influenza vaccination.
Control Group
Children who are active patients of 10 diverse pediatric and family medicine practices and who had at least one visit between 3/1/2011 and 2/29/2012 will serve as the control group; n=38,626. They will receive the 4 Pillars Toolkit and early season vaccine in Year 2.
Overall Study
STARTED
49039
38626
Overall Study
COMPLETED
49039
38626
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

From Innovation to Solutions: Childhood Influenza Vaccination Planning

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Intervention Group
n=43293 Participants
Children in 10 diverse pediatric and family medicine practices. Baseline group are active patients of the practices with a visit between 3/1/2010 and 2/28/2011.
Control Group
n=38306 Participants
Children in 10 diverse pediatric and family practices. Baseline group are active patients of the practices with a visit between 3/1/2010 and 2/28/2011.
Total
n=81599 Participants
Total of all reporting groups
Age, Continuous
7.3 years
STANDARD_DEVIATION 4.8 • n=93 Participants
7.1 years
STANDARD_DEVIATION 5.2 • n=4 Participants
7.2 years
STANDARD_DEVIATION 5 • n=27 Participants
Sex: Female, Male
Female
21560 Participants
n=93 Participants
18540 Participants
n=4 Participants
40100 Participants
n=27 Participants
Sex: Female, Male
Male
21733 Participants
n=93 Participants
19766 Participants
n=4 Participants
41499 Participants
n=27 Participants
Region of Enrollment
United States
43293 children at sites
n=93 Participants
38306 children at sites
n=4 Participants
81599 children at sites
n=27 Participants

PRIMARY outcome

Timeframe: 3/1/2011-2/29/2012

Influenza vaccination rates in each arm at the end of year 1

Outcome measures

Outcome measures
Measure
Intervention Group
n=49039 Participants
Children seen in 10 diverse pediatric and family medicine practices between 3/1/2011 and 2/29/2012.
Control Group
n=38626 Participants
Children with a visit between 3/1/2011 and 2/29/2012 in 10 diverse pediatric and family practices.
Primary Outcome
26432 participants vaccinated out of all
19352 participants vaccinated out of all

SECONDARY outcome

Timeframe: End of February 2012

Two staff members from each site were surveyed as to usefulness/effectiveness of a list of strategies recommended in the toolkit to increase vaccination rates. Values (range = 1-100 with 1 being not at all effective and 100 being highly effective) were averaged and used as an effectiveness score for each strategy. The average value for each site was combined with all sites and averaged for each strategy. (actual range = 20.6-90.7).

Outcome measures

Outcome measures
Measure
Intervention Group
n=20 Participants
Children seen in 10 diverse pediatric and family medicine practices between 3/1/2011 and 2/29/2012.
Control Group
Children with a visit between 3/1/2011 and 2/29/2012 in 10 diverse pediatric and family practices.
Effectiveness Score
75 units on a scale
Standard Deviation 14

Adverse Events

Intervention Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Richard K. Zimmerman

University of Pittsburgh

Phone: 412-383-2355

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place